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Esophageal Endoscopic Ultrasound
With Fine-Needle Aspiration With an
On-site Cytopathologist*
High Accuracy for the Diagnosis of Mediastinal
Lymphadenopathy
Kurt G. Tournoy, PhD; Marleen M. Praet, PhD; Georges Van Maele, PhD; and
Jan P. Van Meerbeeck, PhD
Study objectives: To analyze the accuracy of esophageal endoscopic ultrasound (EUS) with
real-time, guided fine-needle aspiration (EUS-FNA) with an on-site cytopathologist in patients
with (presumed) lung cancer presenting with mediastinal lymphadenopathy (ML) or a suspect left
adrenal gland (LAG).
Design: A single-center prospective study.
Patients: Sixty-seven outpatients with (presumed) lung cancer with ML or a suspect LAG on either
CT and/or positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) scan.
Interventions: All patients underwent EUS-FNA under conscious sedation. A cytopathologist was
present during all procedures.
Measurements: EUS with and without fine-needle aspiration (FNA) as compared to FDG-PET was
evaluated for accuracy in diagnosing cancer, safety, and rate of avoidance for further surgery.
Results: Of 67 consecutive patients (56 men; median age, 64 years), malignant ML or LAG were
found in 47 patients (70.1%). In 20 patients (29.9%) without EUS-FNA proof of malignancy,
confirmation was obtained by surgical procedure in 13 patients (sarcoidosis [n  5], infection
[n  1], lung cancer [n  7]) or by clinical follow-up in 5 patients suggesting benign disease.
Sixty-five patients were included in the calculation of test characteristics. With malignancy as an
end point, the accuracy for EUS-FNA was 100%. This was better than EUS without FNA
(accuracy, 75.4%; p < 0.001) or FDG-PET (accuracy, 75.0% [n  28]; p  0.0011). When using
final histopathologic diagnosis as an end point, the accuracy of EUS-FNA was 92.3%, since
EUS-FNA was unable to show noncaseating granulomas in those patients with sarcoidosis
diagnosed after mediastinoscopy. Related to the presence of the in situ cytopathologist, there
were no inconclusive samples. No adverse events were recorded, and 67.7% of surgical
interventions were avoided following EUS-FNA.
Conclusions: The accuracy in this series of EUS-FNA with cytopathologist-assisted rapid on-site
evaluation is high. The technique is safe and greatly reduces the number of surgical
interventions. (CHEST 2005; 128:3004–3009)
Key words: endoscopic ultrasound; fine-needle aspiration; lung cancer; mediastinum; rapid on-site evaluation
Abbreviations: EUS esophageal endoscopic ultrasound; EUS-FNA  esophageal endoscopic ultrasound with
real-time, guided fine-needle aspiration; FDG-PET positron emission tomography with 18F-fluorodeoxyglucose;
FNA fine-needle aspiration; LAG  left adrenal gland; ML  mediastinal lymphadenopathy; ROSE rapid on-site
evaluation; TBNA transbronchial needle aspiration
T he implementation of new diagnostic tools inroutine medical practice follows extensive pre-
clinical and clinical testing. Curved linear esophageal
endoscopic ultrasound (EUS) with real-time guided
fine-needle aspiration (EUS-FNA) is a fairly new
tool for chest physicians in the diagnostic approach
of mediastinal lymphadenopathy (ML).1,2
Diagnosis of ML in patients with presumed lung
cancer remains a challenge since treatment and
prognosis are dictated by tumor stage. The accuracy
broncoscopy
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of the CT scan to predict ML tumor invasion is
limited.3 Positron emission tomography with 18F-
fluorodeoxyglucose (FDG-PET) is more accurate for
evaluating the mediastinum.4 However, although
FDG-PET has a good negative predictive value
( 93%), it has a low specificity.5 Therefore, the
current recommendation is to obtain pathologic con-
firmation of ML in patients with (presumed) lung
cancer in whom CT or FDG-PET show ML. A
surgical procedure (mediastinoscopy, thoracoscopy,
or thoracotomy) is considered the “gold standard.”6
Transbronchial needle aspiration (TBNA) is advo-
cated by some specialized groups.7 However, TBNA
does not have real-time puncture guidance, and its
accuracy is highly operator dependent. Endobron-
chial ultrasound with real-time guided puncture is a
new technique for staging of the mediastinum. The
technique is promising but still experimental.1,8
The combined use of radial and linear EUS for
investigation of mediastinal structures is well estab-
lished in gastroenterology. In contrast with radial
EUS, which is characterized by high-frequency (20
Mhz), detailed images but which does not allow
fine-needle aspiration (FNA), linear EUS-FNA (5 to
10 Mhz) has a deeper tissue penetration. Hence, it
allows real-time guided FNA but is unable to dis-
criminate mediastinal pleural layers. Linear EUS-
FNA therefore needs to be used with caution for
making decisions about direct mediastinal invasion
through the pleural layers.9 Nonrandomized tri-
als10–15 report encouraging results of EUS tech-
niques for the staging of (presumed) lung cancer
with a good specificity but variable sensitivity (0.72
to 0.97) in analyzing ML. However, most of these
reports10–13 were performed with the sequential use
of radial and linear EUS. Few reports14,15 studied
the role of the linear EUS-FNA only, and were
performed in selected patients with FDG-PET–
positive ML.
Rapid on-site evaluation (ROSE) is comparable
with intraoperative frozen-section examination and
requires at least the presence of a laboratory assistant
in order to process the freshly obtained material and
to report to the endoscopist whether the obtained
material is adequate for diagnosis. Although ROSE
has been shown to improve the diagnostic yield of
endoscopic procedures, there is still a problem of
high numbers of inconclusive smear results.14 Sev-
eral investigators14 hinted at but never assessed the
potential benefit of an on-site cytopathologist. We
report the accuracy of esophageal EUS-FNA with
cytopathologist-assisted ROSE in consecutive pa-
tients with ML or a suspect left adrenal gland (LAG).
Materials and Methods
Patients
Consecutive patients presenting in a pulmonary department
with suspect ML16 at levels 2, 4, 5, 7, 8, and 9, or a suspect LAG
were prospectively investigated with EUS-FNA. ML or the LAG
was considered suspect when the transversal diameter was  10
mm on CT scan or if it was FDG positive on the positron
emission tomography scan. All patients would routinely have
been scheduled for further diagnostic procedures, either by
mediastinoscopy, thoracoscopy, thoracotomy, or adrenal punc-
ture.
Procedure and Design
A curved linear scanning ultrasound endoscope (GF-UCT160-
OL5; Olympus; Aartselaar, Belgium) connected to an ultrasound
unit (ALOKA; Mechelen, Belgium) was used in this series. The
investigation was performed by a trained operator (K.G.T.) in an
outpatient setting with a patient under conscious sedation (IV
fractions of midazolam, 1 mg, until convenient for patient and
investigator) while monitoring the pulse rate and peripheral
oxygen saturation.17 The endoscope was guided into the stomach
to scan the LAG area and the area around the celiac trunk. After
retraction into the esophagus, the mediastinum was evaluated by
scanning 360° transaxially at intervals of approximately 1 cm
upward to ML level 2. The MLs were identified as nonpulsating
regions with round, ellipsoid, crescent, or triangular shapes. All
MLs measuring  3 mm on one of the axes were considered.
These were considered suspect if one of the following character-
istics were present: hypoechogeneity, sharp edges, round shape,
and largest diameter  10 mm. Absence of major blood vessels
was confirmed by Doppler flow in the region of interest. The
largest diameter of the ML was measured. All punctures were
performed with a 22-gauge fine needle (EUS-needle; Olympus;
Aartselaar, Belgium). Only one needle per procedure was used.
Suspect MLs ipsilateral to the lung lesion were only punctured if
contralateral MLs were either considered not suspect or negative
at puncture.
In those patients with positive ML or LAG findings after
EUS-FNA, no additional confirmation of malignancy was done.
We assumed that none of the biopsy results were false-positive
since care was taken not to puncture primary tumors. A surgical
intervention was proposed in those patients with ML but negative
EUS-FNA findings. In some cases, an extended clinical/radio-
logic follow-up documenting absence of disease progression was
considered as a proof for benign underlying disease.
Sample Processing
Smears of the aspirates obtained by EUS-FNA were processed
in situ. For ROSE, the cytotechnician and cytopathologist
(M.M.P.) were called once the first puncture was initiated. They
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evaluated the cellular contents of the air-dried specimens on-site
with a quick staining method (Diff-Quick; Medicon Diagnostics;
Dortmund, Germany). If a specimen was considered inadequate,
additional punctures were performed with the total number of
punctures being noted. If necessary, several lymph nodes were
sampled. Specimens were categorized as positive (tumor cells),
negative (lymphoid but no tumor cells), or inconclusive (poor
cellularity). Punctures were continued until the cytopathologist
was able to make a formal conclusion. Depending on the amount
of material, additional Papanicolaou (with previous short fixation)
and Giemsa staining were performed.
Statistical Analysis
All categorical variables are reported as proportions. Continu-
ous variables are reported as medians and minimum-maximum
range. Comparison of proportions (accuracy analysis) was done
with a Z test. A two-sided p 0.05 was considered statistically
significant. The analysis was done using statistical software (SPSS
12.0; SPSS; Chicago, IL).
Results
Patients and Procedure Characteristics
Between March 2004 and March 2005, 67 consec-
utive patients with suspect ML or LAG were regis-
tered. Demographic and procedural characteristics
are shown in Table 1.
Referral for EUS-FNA was for staging reasons in
30 patients (44.8%) in whom proof of non-small cell
lung cancer was already obtained. Thirty-seven pa-
tients (55.2%) had suspect ML or LAG without
formal proof. FDG-PET data were available in 28
patients (41.8%).
With EUS, we visualized suspect ML or LAG in
one station in 24 patients (35.8%), in two stations in
20 patients (29.9%), in three stations in 16 patients
(23.9%), and in four to five stations in 7 patients
(10.5%). Subcarinal ML was most frequently de-
tected (89.6% of the patients), followed by the
closely adjacent regions 4L and 5 (together, 73.2%).
EUS indicated a suspect LAG in six patients (9.0%).
The primary tumor was observed in 17.9% but was
never punctured. A median of three punctures
(range, one to eight punctures) was performed per
patient.
The median use of midazolam was 3.0 mg per
procedure, and the median duration of the proce-
dure was 45 min. No complications or adverse events
were reported.
Results of EUS-FNA
The outcome of this series of patients is shown in
Figure 1. In 20 patients (29.9%), no malignancy was
found with EUS-FNA. Of this latter group, 13
(19.4%) underwent a surgical procedure. By means
of mediastinoscopy, granulomatous disease sugges-
tive for sarcoidosis was diagnosed in five patients. Of
the seven operated lung cancer patients, all had a
pN0–1 stage. Nonspecific inflammatory changes
were diagnosed in one patient that post hoc were
explained in the context of tuberculosis. In five
patients in whom no surgical procedure was per-
formed, the clinical follow-up of at least 5 months
suggested a nonmalignant cause of ML. There were
two patients (3.0%) with negative EUS-FNA find-
ings in whom no confirmation about the nature of
the ML was obtained because of patient-related
reasons.
In 47 patients (70.1%), a malignant ML or LAG
were detected with EUS-FNA. When excluding the
five patients with LAG involvement, 67.7% of
the patients in whom a surgical intervention to stage
the mediastinum was planned were not referred
to the surgeon. Regions 5, 8R, 8L, 9R, 9L, and the
LAG are targets that are out of reach for cervical
mediastinoscopy. These were assessed by EUS-FNA
in 27 patients (40.3%) and showed malignancy in 19
patients (70.4%).
Table 2 shows the final diagnosis of the ML
obtained after all procedures. The characteristics
of the tumor obtained with EUS-FNA in the 47
patients were compatible with non-small cell lung
cancer in 42 patients. All three main subtypes of
Table 1—Demographic Characteristics of the Patients
and EUS-FNA Procedure Characteristics*
Variables Data
Patients, No. 67
Median age, yr (range) 64 (27–81)
Gender
Male 56 (83.6)
Female 11 (16.4)
Aim of the procedure
Diagnostic 37 (55.2)
Staging only (known malignancy) 30 (44.8)
Position of lymph nodes detected on EUS
( 3 mm)
2R 2 (3.0)
2L 1 (1.5)
4R 1 (1.5)
4L 20 (29.9)
5 29 (43.3)
7 60 (89.6)
8R 8 (11.9)
8L 12 (17.9)
9R 3 (4.5)
9L 3 (4.5)
LAG 6 (9.0)
EUS visualization of primary tumor 12 (17.9)
Median duration of the procedure, min (range) 45 (20–75)
Median midazolam dose, mg (range) 3.0 (0.0–7.5)
Median of largest lymph node axis, mm (range) 23 (4–75)
Median EUS passes, No. (range) 3 (1–8)
*Data are presented as No. (%) unless otherwise indicated.
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non-small cell lung cancer were present in this
series, with the subtype of epidermoid epithelioma
being most frequently detected. In three patients,
we found small cell lung cancer, while two cases of
metastasis of other cancers were found (one renal
cell carcinoma and one bladder carcinoma).
In 53 patients in whom only one station was
punctured, proof of malignancy was found in 43
patients (81.1%). In 14 patients in whom more than
one station was punctured, malignancy was shown in
only 4 patients (28.6%), indicating that the finding of
one negative lymph node station with EUS-FNA
does not preclude malignant invasion of another
station.
Operating Characteristics of EUS and EUS-FNA as
Compared With FDG-PET
The operating characteristics for EUS and EUS-
FNA were calculated for the 65 patients in whom a
final diagnosis was obtained (Table 3). When taking
malignancy as an end point, the accuracy of EUS
without FNA is similar to the accuracy of the
FDG-PET scan (75.0% vs 75.4%, p  not signifi-
cant). EUS-FNA has an accuracy of 100% as com-
pared to both EUS without FNA (p 0.001) and
FDG-PET (p 0.0011). When taking the final di-
agnosis as an end point, the accuracy of EUS-FNA is
92.3%.
Table 3—Comparison of Test Characteristics of FDG-
PET, EUS Without FNA, and EUS-FNA With
Mediastinal Malignancy as an End Point*
Variables
FDG-PET
(n  24)
EUS
(n  65)
EUS-FNA
(n  65)
Malignant ML or
LAG prevalence
71.4 72.3 72.3
Sensitivity 85.0 (62–91) 93.6 (80–96) 100 (92–100)
Specificity 50.0 (15–84) 27.8 (9–53) 100 (81–100)
Positive predictive
value
81.0 (58–89) 77.2 (64–82) 100 (92–100)
Negative predictive
value
57.1 (18–90) 62.5 (24–91) 100 (81–100)
Accuracy 75.0 75.4 100
*Data are presented as % or % (95% confidence interval).
Figure 1. Management of patients based on the results of EUS-FNA.
Table 2—Final Pathology Diagnosis of the Mediastinal
Lymph Nodes in the Study Population*
Diagnosis No. (%)
Mediastinal malignancy 47 (70.1)
Lung cancer
Non-small cell carcinoma, adenocarcinoma 12 (17.9)
Non-small cell carcinoma, epidermoid
epithelioma
18 (26.9)
Non-small cell carcinoma, large cell 12 (17.9)
Small cell carcinoma 3 (4.5)
Other cancers 2 (3.0)
No mediastinal malignancy 18 (26.9)
Benign or reactive lymph node tissue 13 (19.4)
Granulomatous lung disease/sarcoidosis 5 (7.5)
*In two cases (3.0%), no final diagnosis was obtained due to
patient-related reasons.
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Discussion
In this 1-year series of consecutive patients, EUS-
FNA with cytopathologist-assisted ROSE resulted in
a high diagnostic overall accuracy without complica-
tions and with a high avoidance rate of surgical
procedures. The evaluation of lymph nodes with
imaging techniques is unsatisfactory.18 Tissue diag-
nosis of enlarged ML on CT or mediastinal FDG-
PET hot spots is hence still warranted.19 Retrospec-
tive and uncontrolled prospective series10–15,20–22
reported on EUS-FNA as a tool in lung cancer
staging. Its test characteristics not only depend on
the procedure characteristics but are also influenced
by the selection bias of the study population. In
patients with suspect lymph nodes on CT scan, EUS
with or without FNA showed a sensitivity of 0.72 to
0.97 and a specificity of 0.81 to 1.00.10–13,20–22 As
these studies originated in gastroenterology depart-
ments, the patients were often investigated first with
radial EUS (without the possibility of FNA) followed
by linear EUS-FNA. By consequence, sensitivity in
these series includes both cases of positive FNA
findings of ML and of T4 extension shown by means
of radial EUS. In patients with mediastinal hot spots
on FDG-PET, Kramer et al14 showed prospectively
that EUS-FNA detected 50 of 69 patients with
malignant ML, resulting in a sensitivity of 72% for
detecting mediastinal malignancy. Similarly, An-
nema et al15 showed that EUS-FNA was able to
diagnose N2 or N3 in 89%, provided the patient had
FDG-PET–positive lesions in the mediastinum.
The high accuracy and sensitivity of our series, in
patients with suspect ML or LAG, is superior to
earlier reports of EUS-FNA.10–15,20–22 We argue that
the presence of a cytopathologist at the ROSE
contributed to this result. False-negative rates vary in
the literature up to 20% and even 40%.10,14 Most
centers perform ROSE by a laboratory technician
only. Despite ROSE, inconclusive smears represent
up to one third of the patients after FNA.14 ROSE
resulted in our series in the absence inconclusive
smear results, as we kept puncturing until the cyto-
pathologist indicated there was enough material for
making a conclusive pathology report. This approach
is confirmed by a study23 in which ROSE with a
cytopathologist significantly improved the yield of
endoscopic FNA procedures. Another report7 also
confirmed this finding for TBNA and calculated that
a plateau in the yield of malignancy is reached after
seven punctures. It is indeed neither practical nor
convenient for patients and investigators to perform
a standard set of seven to eight punctures in order to
avoid ROSE.
Despite the presence of a cytopathologist, we
failed to come to a more specific diagnosis in case no
malignancy was found with EUS-FNA. The diagno-
sis of granulomatous ML appears to be especially
challenging. Other series10,24 reported the possibility
of finding granulomas in FNA smears. Wildi et al25
investigated this in a retrospective series in which 35
of 124 patients had granulomatous ML diagnosed
with EUS-FNA, while only 3 patients with sarcoid-
osis had false-negative findings. However, the main
criticism is that the methodology in this study was
not uniform since all their patients were investigated
with radial EUS followed by linear EUS, and since
different-gauged needles (19-gauge) as well as Tru-
cut needles were applied. Moreover, the results were
not controlled with an invasive surgical procedure as
“gold standard.” A recent study26 performed in con-
secutive patients with a high suspicion for sarcoidosis
indicated a sensitivity of 82% for EUS-FNA. The
false-negative samples in this study were explained to
be the consequence of ML fibrosis, as often seen in
stage II sarcoidosis.
The limitations of this observational study are
obvious: first, all patients were selected because of
abnormal CT or FDG-PET findings at the time of
referral. Moreover, an inherent bias is the fact that
all patients had ML reachable with EUS. In our
series, there were no patients with suspect ML
situated uniquely at level 6 (para-aortic ML) or
pretracheally. Lastly, we relied for our analysis on a
composite “gold standard” that used results obtained
by EUS-FNA, surgery, and clinical follow-up. One
might reason that all patients should be subjected to
a surgical procedure to exclude possible false-posi-
tive EUS-FNA results. We judged it unethical to
subject patients with malignant disease to further
diagnostic surgery in order to verify the obtained
results. This is an approach that is comparable to
other reports in this field.24
A clinical relevant consequence remains the fact
that a significant number of patients were not re-
ferred to the surgeon because of proof of mediastinal
involvement after EUS-FNA. This figure of avoided
procedures is comparable to that obtained in patients
with FDG-PET–positive ML, in which EUS-FNA
avoided diagnostic surgery in 62 to 69%.14,15 The fact
that in our series 40% of the patients were punctured
at lymph node regions that are out of reach for
cervical mediastinoscopy indicates that an important
number of the patients would have undergone tho-
racotomy or video-assisted thoracoscopy when EUS-
FNA was not available.
No adverse events were recorded in this study.
This compares with findings in other studies14–15
performing FNA with 22-gauge needles. Although
there is an inherent negative publication bias, there
is one report27 of life-threatening mediastinitis oc-
curring after a cyst was punctured. Another study28
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compared the diagnostic yield of a 19-gauge Trucut
needles with classic 22-gauge aspiration needles.
While Trucut needles did not result in better accu-
racy, they induced mediastinitis and bleeding.
Whether 19-gauge aspiration needles play can play a
role in the diagnosis of granulomatous disease re-
mains unclear.
In conclusion, we show that EUS-FNA has an
excellent accuracy when performed with cyto-
pathologist-assisted ROSE. We confirm that the
technique is feasible, safe, and avoids further surgical
staging in a significant number of patients with
suspect ML.
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